Evelina Martinenaite

Medicine & Life Sciences

1. T-Lymphocytes 100%
2. Arginase 88%
3. Vaccines 72%
4. Tumor Microenvironment 60%
5. Vaccination 54%
6. Neoplasms 51%
7. Peptides 46%
8. Subunit Vaccines 40%
9. Epitopes 31%
10. Calreticulin 28%
11. Immunosuppressive Agents 27%
12. Immunity 21%
13. Melanoma 20%
14. Ligands 19%
15. c-Mer Tyrosine Kinase 18%
16. Tumor-Infiltrating Lymphocytes 18%
17. T-Lymphocyte Epitopes 17%
18. Mutation 17%
19. Exons 16%
20. Tissue Donors 14%
21. Cancer Vaccines 14%
22. Nivolumab 13%
23. Indoleamine-Pyrrole 2,3,-Dioxygenase 13%
24. Blood Cells 13%
25. Galectin 3 13%
26. Immunoglobulin Heavy Chains 13%
27. Dendritic Cells 13%
28. Follicular Lymphoma 12%
29. B-Cell Chronic Lymphocytic Leukemia 10%
30. Enzymes 10%
31. Transforming Growth Factors 10%
32. Therapeutics 10%
33. Adaptive Immunity 10%
34. Multiple Myeloma 10%
35. Cell- and Tissue-Based Therapy 9%
36. Pancreatic Neoplasms 9%
37. Transforming Growth Factor beta 9%
38. montanide ISA 51 9%
39. HLA-A2 Antigen 9%
40. Prostatic Neoplasms 8%
41. Clinical Trials 8%
42. Arginine 7%
43. Cytokines 7%
44. Safety 7%
45. Vemurafenib 7%
46. Delayed Hypersensitivity 6%
47. Macrophages 6%
48. Vaccine Immunogenicity 6%
49. Injection Site Reaction 5%
50. Immunosuppression 5%